Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: A US administrative claims database study

Respiratory Research

Volumn 16, Issue 1, 2015, Pages

  Kern, David M ^a   Davis, Jill ^b   Williams, Setareh A ^b   Tunceli, Ozgur ^a   Wu, Bingcao ^a   Hollis, Sally ^b   Strange, Charlie ^c   Trudo, Frank ^b  

^a HEALTHCORE INC   (United States)

^b ASTRAZENECA   (United Kingdom)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Administrative claims; Chronic obstructive pulmonary disease (COPD); Comparative effectiveness; Controller treatments; Inhaled corticosteroid long acting 2< inf> agonist combinations (ICS LABA)

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; BRONCHODILATING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OUTCOME ASSESSMENT; PNEUMONIA; UNITED STATES; ADMINISTRATIVE CLAIMS (HEALTH CARE); AGED; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDY;

ADMINISTRATION, INHALATION; ADMINISTRATIVE CLAIMS, HEALTHCARE; AGED; BRONCHODILATOR AGENTS; BUDESONIDE, FORMOTEROL FUMARATE DRUG COMBINATION; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE DRUG COMBINATION; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84928318325     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-015-0210-x     Document Type: Article

References (25)

1. American Lung Association. COPD fact sheet. 2011. Available from: http://www.lung.org/lung-disease/copd/resources/facts-figures/COPD-Fact-Sheet.html . Last accessed June 6, 2013.
2. What is COPD? National Heart Lung and Blood Institute; U.S.Department of Health & Human Services, 2013. Available from: http://www.nhlbi.nih.gov/health/health-topics/topics/copd . Last accessed June 20, 2013.
3. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. Respir Care. 2002;47(10):1184-99.
4. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121(5 Suppl):121S-6.
5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD, 2014. Available from: http://www.goldcopd.org . Last accessed December 17, 2014.
6. AstraZeneca LP. SYMABICORT Prescribing Information. 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021929s021lbl.pdf. Last accessed June 20, 2013.
7. GlaxoSmithKline. Advair DISKUS Package Insert, 2014. Available from: https://www.gsksource.com/gskprm/htdocs/documents/ADVAIR-DISKUS-PI-MG.PDF Last accessed October 22, 2014.
8. Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014;3:CD010844.
9. Mapel DW, Roberts MH. Management of asthma and chronic obstructive pulmonary disease with combination inhaled corticosteroids and long-acting beta-agonists: a review of comparative effectiveness research. Drugs. 2014;74(7):737-55.
10. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347-65.
11. Roberts M, Mapel D, Petersen H, Blanchette C, Ramachandran S. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management. J Med Econ. 2011;14(6):769-76.
12. Blais L, Forget A, Ramachandran S. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clin Ther. 2010;32(7):1320-8.
13. Larsson K, Janson C, Lisspers K, et al. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J Intern Med. 2013;273(6):584-94.
14. Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346:f3306.
15. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD010115.
16. Mapel D, Schum M, Yood M, Brown J, Miller D, Davis K. Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators. Prim Care Respir J. 2010;19(2):109-17.
17. Nau DP. Proportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence. 2014. Available from: http://www.pqaalliance.org/. Last accessed October 20, 2014.
18. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med. 2008;27(12):2037-49.
19. Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol. 2010;172(9):1092-7.
20. Parsons L. Reducing bias in a propensity score matched-pair sample using greedy matching techniques; In SAS SUGI 26, 2001, Paper 214-226. Available from: http://www2.sas.com/proceedings/sugi26/p214-26.pdf (SUGI 26), 214-226.
21. Lee B, Lessler J, Stuart E. Improving propensity score weighting using machine learning. Stat Med. 2010;29:337-46.
22. Liaw A, Wiener M. Classification and regression by random forest. R News. 2002;2(3):18-22.
23. Sekhon JS. Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Softw 2014, 42(7)
24. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029-36.
25. Halpin DM, Gray J, Edwards SJ, Morais J, Singh D. Budesonide/formoterol vs salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J Clin Pract. 2011;65(7):764-74.